TARA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Protara Therapeutics Inc (TARA) is not a strong buy for a beginner investor with a long-term horizon at this time. The stock lacks significant positive catalysts, has weak financial performance, and no strong trading signals. While the analyst rating is positive, the technical and options data do not indicate a compelling entry point.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 49.032, showing no clear signal. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading below the pivot level of 6.739, with support at 6.318 and resistance at 7.159.
Analyst coverage initiated by Piper Sandler with an Overweight rating and a $24 price target, citing three potentially substantial market opportunities.
No recent news or significant trading trends from hedge funds or insiders. Financial performance is weak, with no revenue and a significant net loss in the latest quarter. The stock has a 50% chance to decline 1.96% in the next day.
In Q3 2025, revenue remained at $0 with no YoY growth. Net income improved by 18.17% YoY but remains negative at -$13.26M. EPS dropped by 38% YoY to -0.31, indicating worsening profitability.
Piper Sandler initiated coverage with an Overweight rating and a $24 price target, highlighting the company's under-the-radar status and potential market opportunities.
